Sign in
Taking peopleNo phase

The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With Pneumonia

Key facts

Who runs it
Far Eastern Memorial Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
84 people, planned
Started
19 Oct 2026
Expected to end
31 Jul 2028
Type of study
Interventional, 7 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sunflower oil inhalation
  • 1% Linalool inhalation
  • Wintergreen essential oil inhalation
Record updated
26 October 2026

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Primary diagnosis of pneumonia with dyspnea symptoms
  • Admitted with ICD-10 diagnosis codes: Influenza and viral pneumonia (J10-J12), Bacterial pneumonia (J13-J15), Other infectious agents (J16-J17), or Unspecified organism pneumonia (J18.9)
  • Aged 18 to 90 years
  • Clear consciousness (Glasgow Coma Scale: 15) with normal mental and behavioral capacity
  • Able to communicate verbally or non-verbally and comprehend Mandarin or Taiwanese

Who cannot take part

  • Currently receiving non-invasive positive pressure ventilation (NIPPV, BiPAP), high-flow nasal cannula (HFNC), or oxygen masks (such as Simple mask, Non-rebreathing mask)
  • Dementia (including Alzheimer's disease, Parkinson's disease, etc.)
  • Acute psychiatric symptoms precluding communication
  • Known allergy or hypersensitivity to salicylates, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Anosmia or severe nasal diseases
  • History of asthma
  • History of very severe chronic obstructive pulmonary disease (COPD): GOLD stage 4 (FEV1 < 30% predicted)
  • Pregnant or lactating women

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Pneumonia or dyspnea

This trial is currently available in Taiwan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pneumonia is a major public health concern globally and domestically. Dyspnea experienced by hospitalized pneumonia patients often induces anxiety and psychological distress. Wintergreen essential oil, primarily composed of methyl salicylate, is commonly used for comfort care and respiratory relief. This study aims to evaluate the effects of wintergreen essential oil inhalation on dyspnea, physiological parameters, laboratory data, pulmonary function, and subjective comfort in hospitalized pneumonia patients.

The 7 groups in the trial

  • Waiting Control GroupNo study treatment, for comparison

    Participants receive standard routine medical and nursing care for pneumonia without receiving any essential oil or placebo oil inhalation intervention during the study period.

  • Placebo Control GroupPlacebo, for comparison

    Participants receive routine care plus sunflower oil inhalation. A dose of 0.5 mL (10 drops) of pure sunflower oil is applied to a 2-inch gauze and held 5 cm from the participant's nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.

    Treatment: Sunflower oil inhalation

  • Positive Control Group (1% Linalool)Existing treatment, for comparison

    Participants receive routine care plus 1% linalool inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.

    Treatment: 1% Linalool inhalation

  • 0.5% Wintergreen Oil GroupTreatment being tested

    Participants receive routine care plus 0.5% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.

    Treatment: Wintergreen essential oil inhalation

  • 1% Wintergreen Oil GroupTreatment being tested

    Participants receive routine care plus 1% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.

    Treatment: Wintergreen essential oil inhalation

  • 2% Wintergreen Oil GroupTreatment being tested

    Participants receive routine care plus 2% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.

    Treatment: Wintergreen essential oil inhalation

  • 3% Wintergreen Oil GroupTreatment being tested

    Participants receive routine care plus 3% wintergreen essential oil inhalation (diluted in sunflower oil). A dose of 0.5 mL (10 drops) is applied to a 2-inch gauze held 5 cm from the nose for 8 deep breaths, administered 3 times daily for 3 consecutive days.

    Treatment: Wintergreen essential oil inhalation

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07894835, who can take part
Record updated
26 October 2026